Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.35)
# 2,616
Out of 5,113 analysts
53
Total ratings
32%
Success rate
5.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Overweight | n/a | $5.40 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $9.23 | +95.02% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.91 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.59 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $80.24 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $45.11 | +121.68% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.97 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $7.37 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.25 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $15.14 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.29 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.23 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $50.50 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.38 | +47.93% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.81 | +362.63% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $24.75 | -67.68% | 1 | Mar 20, 2023 |
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.40
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $9.23
Upside: +95.02%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.91
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $80.24
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $45.11
Upside: +121.68%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.97
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.37
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.25
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.14
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.29
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.23
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $50.50
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.38
Upside: +47.93%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.81
Upside: +362.63%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $24.75
Upside: -67.68%